U.S., Feb. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07380152) titled 'Corticosteroid Therapy in Pulmonary Sequelae of Covid-19' on Dec. 04, 2024.
Brief Summary: Introduction: The new coronavirus (SARS-CoV-2) is a virus with an intense capacity for dissemination and high mortality rate. The main cause of death is viral pneumonia, characterized as organizing pneumonia that responds to treatment with corticosteroids. After 1 month of the acute phase, 25% of patients have complete recovery from lung lesions. However, lung lesions can evolve as persistent interstitial lung disease; it is possible that this persistent disease is also responsive to corticosteroid therapy. There are no controlled and randomize...